2807 |
Practical Question: How We Should Define \"Responsiveness\" to Renal Denervation - HTN and Beyond HTN Indications |
Horst Sievert |
May. 09. 14 |
2806 |
Mechanisms and Clinical Evidence for Expanded Indications (HF, DM, Arrythmia, or Sleep Apnea Improvement) |
David E. Kandzari |
May. 09. 14 |
2805 |
Case Presentation: Beyond BP Control with Renal Denervation (HF, DM, Arrythmia, or Sleep Apnea Improvement) |
Richard R. Heuser |
May. 09. 14 |
2804 |
Renal Denervation: New Techniques, New Devices, and Future Perspective |
Ian T. Meredith |
May. 09. 14 |
2803 |
Real-world Experience: Longterm Outcomes and Unmet Need |
Krishna Rocha-Singh |
May. 09. 14 |
2802 |
Trial Design Lessons, Device Hypertension Trials |
Paul A. Sobotka |
May. 09. 14 |
2801 |
New TAVI Devices |
Martin Bert Leon |
May. 09. 14 |
2800 |
Valve in Valve: Things That You Need to Know |
Bernard R. Chevalier |
May. 09. 14 |
2799 |
TAVI for Intermediate Risk Patients |
Corrado Tamburino |
May. 09. 14 |
2798 |
Complication Management: Paravalve Leak, Stroke, Vascular Complication and Conduction Disturbance |
Raj Makkar |
May. 09. 14 |